Background Methylated gene markers have shown promise in predicting breast cancer outcomes and treatment response. We evaluated whether baseline and changes in tissue and serum methylation levels would predict pathological complete response (pCR) in patients with HER2-negative early breast cancer undergoing preoperative chemotherapy. Methods The TBCRC008 trial investigated pCR following 12 weeks of preoperative carboplatin and albumin-bound paclitaxel ? vorinostat/placebo (n = 62). We measured methylation of a 10-gene panel by quantitative multiplex methylation-specific polymerase chain reaction and expressed results as cumulative methylation index (CMI). We evaluated association between CMI level [baseline, day 15 (D15), and change] and pCR using univariate and multivariable logistic regression models controlling for treatment and hormone receptor (HR) status, and performed exploratory subgroup analyses. Results In univariate analysis, one log unit increase in tissue CMI levels at D15 was associated with 40% lower chance of obtaining pCR (odds ratio, OR 0.60, 95% CI 0.37-0.97; p = 0.037). Subgroup analyses suggested a significant association between tissue D15 CMI levels and pCR in vorinostat-treated [OR 0.44 (0.20, 0.93), p = 0.03], but not placebo-treated patients. Conclusion In this study investigating the predictive roles of tissue and serum CMI levels in patients with early breast cancer for the first time, we demonstrate that high D15 tissue CMI levels may predict poor response. Larger studies and improved analytical procedures to detect methylated gene markers in early stage breast cancer are needed. TBCRC008 is registered on ClinicalTrials.gov (NCT00616967). 
Introduction
Long-term outcomes for the majority of patients with breast cancer are excellent, due to early detection and the widespread availability of local and systemic therapies [1] . Nonetheless, some patients will experience recurrence of their breast cancer despite standard treatment approaches. Others will have an excellent prognosis, and may be overtreated [2] . The identification of biomarkers that are prognostic and predictive of response to therapy is therefore of the utmost importance in the management of this disease [3] [4] [5] . Potential biomarkers may be identified through collection of baseline and serial blood and tumor samples incorporated as part of prospectively designed studies.
Aberrant methylation of DNA is characteristic of breast cancer, where hypermethylation of hundreds of cancerspecific genes provides a rich source of biomarkers of detection, prognosis, and prediction of response to therapy [6] [7] [8] [9] . Hypermethylation often results in silencing of important genes such as tumor suppressor genes and those involved with growth regulation that are active in noncancerous breast tissue. Various quantitative techniques [10] [11] [12] , including quantitative multiplex methylationspecific PCR (QM-MSP) [13] [14] [15] [16] , have the ability to robustly detect gene methylation in tumor samples. Tumor tissue methylation has shown promise as a biomarker to predict response to therapy and to prognosticate outcome of disease. In patients with glioma treated with preoperative temozolomide, tissue MGMT methylation predicted favorable progression-free survival (PFS, p \ 0.0001) [17] . Fiegl et al. suggested that NEUROD1 methylation is a chemosensitivity marker in estrogen receptor-negative breast cancer [18] . Other studies in breast cancer have been performed in locally advanced disease to investigate pharmaco-epigenetic effects following preoperative chemotherapy [19, 20] .
Our group and others have recently identified methylated cell-free DNA in serum, shed presumably by circulating or dying tumor cells, as a promising prognostic biomarker, and a predictive biomarker of response to treatment in breast cancer (cMethDNA) [21, 22] and other methylation assays [23] [24] [25] [26] [27] . Unlike technologies used by others, cMethDNA is a quantitative multiplex methylationspecific PCR assay consisting of a panel of up to 10 novel known breast cancer hypermethylated markers. It uses spiked standards for each gene, provides absolute quantitation, and consistently detects cell-free tumor-specific DNA in peripheral blood of patients with metastatic breast cancer with high sensitivity and specificity [21] . In a small validation clinical study of patients with metastatic breast cancer initiating a new course of treatment (n = 140), the assay predicted patient response to chemotherapy early in the course of treatment, and prognosticated outcome [22] . Although established in patients with metastatic breast cancer, cMethDNA has not been previously evaluated in the early breast cancer setting.
We hypothesized that both tissue and serum methylation would be valuable predictive biomarkers in earlier stages of the disease. Specifically, we hypothesized that baseline and changes in tumor tissue (QM-MSP) and serum methylation (cMethDNA) would predict pathologic complete response (pCR) in women receiving preoperative chemotherapy. To test this hypothesis, we performed an exploratory planned biomarker study in women with HER2-negative breast cancer who received preoperative carboplatin and albumin-bound paclitaxel with or without the histone deacetylase (HDAC) inhibitor, vorinostat, through the prospective TBCRC008 clinical trial [28] .
Materials and methods

Clinical trial design
TBCRC008 was a multicenter placebo-controlled trial that compared pCR following 12 weeks of preoperative chemotherapy with or without vorinostat in 62 patients with HER2-negative breast cancer (Fig. 1) [28] . Participants received 12 weeks of preoperative carboplatin (AUC 2 weekly) and nab-paclitaxel (100 mg/m 2 weekly) with vorinostat (400 mg oral daily, days 1-3 of every 7-day period) or a matched placebo. The primary end point was pCR, defined as no viable invasive cancer in the breast and axilla.
Eligible participants for TBCRC008 were women 18 years of age or older, with histologically proven infiltrating carcinoma of the breast who presented with operable, clinical stage T1c, N1-3, or T2-4 lesions, any N; and M0. Tumors must have been HER2-negative and grade 2 or 3, with any estrogen (ER) or progesterone receptor (PR)-status.
After a brief phase I run-in portion, participants in the phase II portion of the study were randomly assigned 1:1 to receive carboplatin and nab-paclitaxel with vorinostat or placebo using permuted block randomization, stratified by hormone receptor status (ER and PR \1% vs. ER or PR C1%) [28] . Additional non-study chemotherapy (doxorubicin and cyclophosphamide, AC) was allowed per treating physician discretion prior to definitive surgery, for patients with incomplete response or disease progression on study treatment. Women signed an informed consent approved by the Institutional Review Boards of participating institutions.
Sample collection and methylation analysis
A study-specific core biopsy and blood sampling (serum) were obtained at baseline and 15 days after the first treatment (D15), preferably about 4 h after taking vorinostat/placebo and prior to receiving carboplatin and nabpaclitaxel. Core biopsy specimens were suspended in 10% buffered formalin, and subsequently embedded in paraffin. Serum samples were processed and stored at -80°C or below prior to analysis. Tissue and serum DNA were extracted and then treated with sodium bisulfite as previously described [13, 21] . Methylation was measured using CMI in quantitative multiplex methylation-specific polymerase chain reaction assays: cMethDNA assay for serum [21] and QM-MSP for tissue [13] . The CMI was calculated as a sum of all gene-specific methylation indexes within a panel of 10 genes which included: HIST1H3C, AKR1B1, GPX7, HOXB4, TMEFF2, RASGRF2, COL6A2, ARH-GEF7, TM6SF1, and RASSF1A. These 10 genes were selected in a previous study following genomewide methylome analyses (Illumina Infinium HumanMethylation27 BeadChip) in tissue and serum, as they were frequently highly methylated in breast tumors of all stages and in serum from patients with metastatic breast cancer. These genes were unmethylated or methylated at low levels in normal breast tissue [29] and in cell-free circulating serum DNA of normal individuals [21] .
Statistical analysis
The objectives of this preplanned exploratory analysis were to evaluate (1) the association of baseline methylation (tissue and serum) with pCR; (2) the association of change (baseline versus D15) in methylation (tissue and serum) with pCR; (3) the effects of vorinostat and other clinical variables on the association between methylation status and pCR [30] .
The analysis population included all patients for whom complete CMI data were available (Table 1) . Only samples where methylation results were available for all genes were evaluated. CMI at baseline and D15 were natural logtransformed as log (Baseline CMI ? 1) and log (D15 CMI ? 1), respectively. Change in CMI was defined as log (D15 CMI ? 1/baseline CMI ? 1).
Distributions of CMI levels at baseline and D15 were evaluated with descriptive statistics, and compared using Wilcoxon-matched-pairs signed rank test. The difference in tissue CMI levels at D15 by treatment arm and by pCR status was compared using nonparametric Mann-Whitney U test. Furthermore, associations between CMI level (baseline, D15, change) and pCR were evaluated using univariate as well as multivariable logistic regression models controlling for treatment arm and hormone receptor status. Additional subgroup analyses were performed to assess the association of CMI level with pCR using logistic regression models, stratified by ER status and treatment arm, respectively.
All tests were considered statistically significant at p \ 0.05. No multiplicity adjustment was made. Analyses were performed using SAS 9.4 (SAS Institute, Cary, NC) and GraphPad Prism (version 5.00 for Windows, GraphPad Software, San Diego, CA, www.graphpad.com). 
Results
Patient characteristics
Demographic and clinical variables from TBCRC008 have been previously published and are summarized in Supplementary Table 1 [ 28] . Approximately 60% of participants had ER/PR-positive tumors, and 60% had positive axillary lymph nodes at study entry. pCR data were available for 60 of 62 patients for this analysis. Two patients with unknown response were considered nonresponders following the intent-to-treat principle. Overall pCR was 27% and was similar in both arms (29% placebo vs. 26% vorinostat). AC chemotherapy was administered prior to definitive surgery in 18 patients deemed to have incomplete response or disease progression on study treatment.
Patient tissue and serum methylations
Available tissue methylation data were evaluated in 58 (baseline), 50 (D15), and 48 (both) patients, and serum methylation data were available in 59 (baseline), 61 (D15), and 58 (both) patients (Fig. 2) . Median tissue CMI levels were 50 (range 0-417) at baseline and 25 (range 0-163) at D15, and median CMI change within individuals between baseline and D15 was 14 (range -310 to 69). Median serum CMI levels were 3 (range 0-124) at baseline and 4 (range 0-90) at D15, and median CMI change was 0 (range -120 to 29) (Fig. 2) . Within individuals, we observed significant changes in tumor content (% tumor in biopsy section, p \ 0.0001; paired T test) and tumor methylation (CMI, p \ 0.0001; Wilcoxon-matched-pairs test) from baseline to D15 (Fig. 3) .
Associations between CMI level and response to therapy
Baseline methylation was not associated with pCR for either tissue or serum. Tissues from patients who achieved pCR had significantly lower methylation at D15 compared to those with no pCR (p = 0.0143) (Fig. 4a) . Supported by the univariate analysis, a one log unit increase in tissue CMI levels at D15 was associated with a 40% lower chance of obtaining a pCR (odds ratio, OR 0.60, 95% CI 0.37-0.97; p = 0.037) ( Table 1) . A similar association was not observed for serum methylation (Table 1) . The distribution of tissue CMI at D15 was further evaluated in vorinostat-treated patients compared to patients receiving placebo. Within individuals, we observed significant decrease in tumor content (p \ 0.0001; paired T test) and in tumor methylation (LogCMI, p \ 0.0001; paired T test) from baseline to D15 irrespective of treatment assignment (Fig. 3) . No significant difference was observed in D15 tissue CMI between treatment arms (tissue: p = 0.607; Figs. 4b, S1 ). Tumor methylation levels of individual genes did not significantly differ between vorinostat and placebo groups, either at baseline or on D15 (Fig. S1) . Interestingly, D15 tumors from individuals who achieved pCR after receiving vorinostat had significantly lower CMI than those that failed to achieve pCR (p = 0.0157). This trend appeared to be less profound in tumors from patients in the placebo arm that did or did not achieve pCR (p = 0.408) ( Fig. 4c ; Supplementary Table 2 ), suggesting a potential interaction between the treatment effect and D15 methylation in tumors.
Multivariable analysis adjusting for treatment arm and hormone receptor status did not show a statistically significant association of tissue or serum CMI with pCR, although a similar trend in magnitude toward association with pCR was observed for D15 and change in tumor tissue CMI (OR 0.67 and 0.57, p = 0.129 and 0.147 respectively) ( Table 2 ). Additional multivariable analyses also failed to demonstrate a statistically significant association of tissue or serum CMI with pCR (Tables 3, 4) .
Subgroup analyses (univariate) suggested a significant association between tissue CMI levels at D15 and pCR in the group treated with vorinostat [tissue OR 0.44 (0.20, 0.93), p = 0.03; serum OR 0.37 (0.13, 1.07), p = 0.07] but not in the placebo group (Supplementary Table 3c, d ). There was no significant association between CMI levels and pCR in patients with hormone receptor-positive breast cancer versus those with triple-negative disease (Supplementary Table 3a , b).
Discussion
In a planned exploratory biomarker analysis from the prospectively designed preoperative TBCRC008 trial, we have evaluated for the first time the predictive roles of tissue and serum CMI levels in patients with early-stage HER2-negative breast cancer treated with preoperative chemotherapy with or without an HDAC inhibitor. We have demonstrated in univariate analysis that an increase in tissue CMI level at D15 was associated with poor response to this therapy and may potentially have a predictive role in the preoperative setting. Our data suggest that lack of an early and robust tumor response to preoperative therapy will result in a greater burden of DNA methylation at this D15 timepoint, i.e., an association of DNA methylation as early as D15 with pCR.
Epigenetic alterations, including abnormal methylation of DNA in the promoter region of important genes, are prevalent in breast cancers and often result in silencing of gene expression [31] . This knowledge has prompted investigation into their clinical significance and whether they can be manipulated to improve patient outcomes [32] . While a few studies have reported the utility of single methylated markers in tissue or serum in predicting response to chemotherapy in both the preoperative and adjuvant settings, there have been no follow-up-validation studies to further support their findings. Changes between baseline and D15 tumor content (% tumor in biopsy section) and methylations were quantified using Wilcoxon-matched pairs test. Significant reductions in both tumor content and methylation were observed at D15 within the study population (''All patients''), as well as vorinostat and placebo groups. Only samples having methylation values for all 10 genes were evaluated DNA methylation in breast cancer gene promoters has been evaluated by QM-MSP in archival tumor and blood samples [22, 23, [33] [34] [35] [36] [37] . Genomewide methylation array analysis has also been performed on 103 primary invasive breast cancers and on 21 normal breast samples, using the Illumina Infinium HumanMethylation27 array [29] . A higher frequency of methylation was noted in hormone receptor-positive tumors compared with HR-negative tumors. The hypermethylated loci in ER-negative tumors, however, were closer to the transcriptional start sites, perhaps indicating a tighter control of transcriptional repression. These studies indicate that methylation of promoter regions of breast cancer-related genes may have utility as potential prognostic biomarkers in breast cancer.
Patients, advocates, and physicians are increasingly aware of the importance of obtaining tumor biopsies, including serial samples, for correlative analyses with the hope of individualizing therapy for future patients. Bloodbased biomarkers, however, may offer a noninvasive and more convenient way to assess prognosis or monitor therapy, which may be more acceptable to patients. cMethDNA underwent preliminary validation in a multisite prospective study on TBCRC005 using serum samples from 141 women at baseline, at week 4, and at first restaging. A CMI was generated on the basis of 6 of the 10 genes tested. In multivariable analyses, an increase in the CMI from baseline to week 4 was associated with worse PFS (p \ 0.001) and progressive disease at first restaging (p \ 0.001). CMI at week 4 was a strong predictor of PFS, even in the presence of circulating tumor cells (p = 0.004). Thus, serum cMethDNA assay can detect advanced breast cancer, may serve as a prognostic biomarker, and has the potential to monitor tumor burden and treatment response in patients with advanced breast cancer [21] . Based on these promising results, we were keen to investigate this blood-based assay in our early breast cancer dataset as described above. Alternative approaches which continue to be studied in the early breast cancer setting include the use of plasma tumor DNA (ptDNA) to predict prognosis and response to therapy [38, 39] . Strengths of our study include the prospective design of the TBCRC008 preoperative clinical trial, with a preplanned exploratory analysis to evaluate the predictive values of serum and tumor methylations. All patients in the study (n = 62) underwent baseline image-guided tumor biopsy, with the majority (59/62) also undergoing a shortinterval follow-up biopsy at D15 [28] . Alongside successful serial collection of blood samples, this study highlights the feasibility of such sample collection for correlative analyses in the preoperative setting in patients with early breast cancer. Limitations of this analysis include the small sample size which may limit the interpretation of our positive findings regarding the association of tissue CMI levels at D15 and response to this therapy, as well as the extent to which the interaction between tissue CMI levels at D15 and treatment response to preoperative therapy may be assessed.
Additional larger prospective studies will be needed to further define the role of gene methylation signatures in predicting clinical outcomes and response to systemic therapy in patients with breast cancer, and indeed other tumor types. Much of the focus to date has been on the advanced breast cancer setting, where ongoing analyses using prospectively collected serum will indeed attempt to answer these important questions in regard to the cMethDNA assay. Based on our observation that there was a significant association between tissue CMI levels at D15 and pCR in those treated with vorinostat but not placebo, consideration should be given for investigating more potent demethylating agents in this setting. Investigations should also consider additional clinical scenarios such as the early detection of recurrent breast cancer after primary surgery. Finally, the development of more sensitive assays which can detect lower levels of DNA methylation in the early breast cancer setting is clearly needed. Close collaboration between basic scientists, clinical investigators, and experts in biomarker development is an essential moving forward step in order to further personalize treatment approaches for patients with breast cancer.
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